New Mexico 2025 Regular Session

New Mexico House Bill HB236

Caption

Notice For Medication Abortions

Impact

This bill imposes new obligations on medical providers by requiring them to post signs related to medication abortions and to provide specific information to patients 24 hours prior to the abortion procedure. Facilities that fail to comply may face fines up to $10,000. While supporters argue that this empowers patients and enhances care, critics contend that it may create additional barriers for individuals seeking abortions, particularly in non-emergency cases.

Summary

House Bill 236, introduced by Representative Jenifer Jones, aims to regulate the provision of medication abortions, specifically those involving the drug mifepristone. The bill mandates that healthcare facilities, including clinics, hospitals, and pharmacies, provide explicit notices to patients seeking medication abortions. The notice informs patients that mifepristone is not always effective and outlines potential options for reversing its intended effects if the second pill has not been taken. This requirement sets a standard for patient information aimed at promoting awareness and informed decisions.

Contention

Notably, the bill includes provisions that allow for civil actions against physicians who do not comply with the notification requirements. Critics of HB236 argue that such legal implications may deter doctors from providing necessary care or may lead to inadvertent lawsuits, thereby impacting patient access to services. Furthermore, the definition of 'medical emergency' used in the bill excludes psychological or emotional conditions, raising concerns about the limitations imposed on patients' rights to make decisions about their health care.

Companion Bills

No companion bills found.

Similar Bills

CA AB54

Access to Safe Abortion Care Act.

HI HB866

Relating To Health Care.

US HB796

Second Chance for Moms Act

HI SB1246

Relating To Health Care.

IN SB0245

Abortion inducing drugs.

SC H3092

Chemically Induced Abortions

US HB679

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

CT SB01355

An Act Concerning Prescription Drugs, Devices And Nonlegend Drugs.